Afatinib Demonstrate Encouraging Efficacy As Well As Safety in Late Stage EGFR-Mutant NSCLC

According to final outcomes of the ASCENT trial, which was came out during the International Association for the Study of Lung Cancer 2021 Targeted Therapies of Lung Cancer Meeting, “Integrating afatinib (Gilotrif) into standard-of-care chemoradiation either with or without surgery showed the encouraging efficacy, feasibility, and safety outcomes in patients with stage-III EGFR mutation +Ve